FDA Awards Priority Review Voucher for Rare Pediatric Disease Drug
March 13, 2025
March 13, 2025
WASHINGTON, March 13 (TNSFR) -- The Food and Drug Administration (FDA) has awarded a priority review voucher to SpringWorks Therapeutics, Inc. for its drug GOMEKLI (mirdametinib), which was approved on February 11, 2025.
The voucher, granted under the Rare Pediatric Disease Priority Review Voucher Program, is designed to incentivize the development of treatments for serious and life-threatening diseases that primarily affect children.
GOMEKLI (mirdametinib) is an oral . . .
The voucher, granted under the Rare Pediatric Disease Priority Review Voucher Program, is designed to incentivize the development of treatments for serious and life-threatening diseases that primarily affect children.
GOMEKLI (mirdametinib) is an oral . . .